Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Cirrhosis

  Free Subscription

Articles published in Z Gastroenterol

Retrieve available abstracts of 20 articles:
HTML format

Single Articles

    November 2021
  1. LABENZ C, Kostev K, Galle PR, Worns MA, et al
    Prescription rates of common medications in patients with decompensated cirrhosis in Germany.
    Z Gastroenterol. 2021 Nov 24. doi: 10.1055/a-1676-4822.
    PubMed     Abstract available

  2. KACZMAREK DJ, Kupczyk P, Schultheiss M, Chang J, et al
    TIPS for the management of stomal variceal bleeding due to cirrhotic and non-cirrhotic portal hypertension.
    Z Gastroenterol. 2021 Nov 5. doi: 10.1055/a-1508-6446.
    PubMed     Abstract available

    September 2021
  3. HONER ZU SIEDERDISSEN C, Schultalbers M, Wubbolding M, Lechte GS, et al
    Impact of the COVID-19 pandemic on patients with liver cirrhosis-the experience of a tertiary center in Germany.
    Z Gastroenterol. 2021;59:954-960.
    PubMed     Abstract available

    August 2021
  4. STAHMEYER JT, Hemmerling M, Burger B, Eberhard S, et al
    [Frequency of diagnosed non-alcololic fatty liver disease (NAFLD) in the German population - An analysis based on health insurance data].
    Z Gastroenterol. 2021;59:851-858.
    PubMed     Abstract available

    June 2021
  5. SCURT FG, Bose K, Canbay A, Mertens PR, et al
    [Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options].
    Z Gastroenterol. 2021;59:560-579.
    PubMed     Abstract available

    March 2021
  6. KUBESCH A, Peiffer KH, Abramowski H, Dultz G, et al
    The presence of liver cirrhosis is a strong negative predictor of survival for patients admitted to the intensive care unit - Cirrhosis in intensive care patients.
    Z Gastroenterol. 2021 Mar 16. doi: 10.1055/a-1401-2387.
    PubMed     Abstract available

    January 2021
  7. GAIRING SJ, Kloeckner R, Pitton MB, Baumgart J, et al
    Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion.
    Z Gastroenterol. 2021;59:43-49.
    PubMed     Abstract available

    December 2020
  8. MICHEL M, Schattenberg JM
    [Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?]
    Z Gastroenterol. 2020;58:1233-1240.
    PubMed     Abstract available

    November 2020
  9. MUCKE MM, Miesbach W, Peiffer KH, Mucke VT, et al
    [Management of hemostasis in gastroenterology critical care].
    Z Gastroenterol. 2020;58:1099-1106.
    PubMed     Abstract available

    September 2020
  10. KABBANI AR, Schultalbers M, Tergast T, Kimmann M, et al
    [Influence of a spontaneous bacterial peritonitis, nosocomial infections and acute-on-chronic liver failure on treatment revenues in patients with decompensated cirrhosis in Germany].
    Z Gastroenterol. 2020;58:855-867.
    PubMed     Abstract available

    June 2020
  11. GUNDLING F, Luxi M, Seidel H, Schepp W, et al
    Small intestinal dysmotility in cirrhotic patients: correlation with severity of liver disease and cirrhosis-associated complications.
    Z Gastroenterol. 2020 Jun 8. doi: 10.1055/a-1162-0357.
    PubMed     Abstract available

    May 2020
  12. SEBODE M, Kloppenburg A, Aigner A, Lohse AW, et al
    Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment.
    Z Gastroenterol. 2020;58:431-438.
    PubMed     Abstract available

  13. ZHELEGU I, Ebert MP, Vogelmann R
    [Current standard of antibiotic prophylaxis in esophageal varices bleeding in Germany].
    Z Gastroenterol. 2020;58:445-450.
    PubMed     Abstract available

    March 2020
  14. SCURT FG, Bose K, Canbay A, Mertens PR, et al
    [Paradigm shift in understanding Acute kidney injury in patients with chronic liver disease: From pathophysiology to defining disease entities].
    Z Gastroenterol. 2020;58:254-266.
    PubMed     Abstract available

    January 2020
  15. MICHEL M, Kalliga E, Labenz C, Straub BK, et al
    A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.
    Z Gastroenterol. 2020;58:57-62.
    PubMed     Abstract available

  16. HUBER Y, Galle PR, Schattenberg JM
    [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?]
    Z Gastroenterol. 2020;58:68-73.
    PubMed     Abstract available

  17. LABENZ C, Adarkwah CC, Worns MA, Miehlke S, et al
    Management of hepatic encephalopathy in Germany: a survey among physicians.
    Z Gastroenterol. 2020;58:49-56.
    PubMed     Abstract available

  18. VOLLMAR J, Stern F, Lackner K, Mildenberger P, et al
    Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort.
    Z Gastroenterol. 2020;58:30-38.
    PubMed     Abstract available

    December 2019
  19. GUNDLING F, Rathmayer M, Koller L, Wilke M, et al
    [Prognostic significance and economic burden of hepatic encephalopathy in liver cirrhosis in German hospitals based on G-DRG data].
    Z Gastroenterol. 2019 Dec 20. doi: 10.1055/a-1068-3138.
    PubMed     Abstract available

    October 2019
  20. ALSENBESY M, Rau M, Weiss J, Gotze O, et al
    A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty liver disease (NAFLD) patients - single-center real-world experience of outpatient clinical practice.
    Z Gastroenterol. 2019;57:1209-1217.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.